Neogap Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$9.6M
- Investors
-
8
Neogap General Information
Description
Developer of a cancer immunotherapy designed to target and eliminate cancer. The company's product identifies optimal neoantigens to target, activate, and multiply T-lymphocytes with the purpose of eradicating cancer, enabling cancer patients to recover from the disease.
Contact Information
Website
www.neogap.seCorporate Office
- Stiftelsen Cancercentrum Karolinska (CCK)
- Visionsgatan 56
- 171 64 Solna
- Sweden
Corporate Office
- Stiftelsen Cancercentrum Karolinska (CCK)
- Visionsgatan 56
- 171 64 Solna
- Sweden
Neogap Timeline
Neogap Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 11-Feb-2026 | $9.6M | Completed | Clinical Trials - Phase 2 | ||
| 7. Accelerator/Incubator | 20-Jun-2025 | Completed | Clinical Trials - Phase 2 | |||
| 6. Accelerator/Incubator | 29-Apr-2025 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 10-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 01-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 02-Mar-2023 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series A) | 22-Dec-2021 | $6.41M | $6.41M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 |
Neogap Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Neogap Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neogap Patents
Neogap Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021299974-A1 | Immunotherapy | Pending | 01-Jul-2020 | ||
| CA-3183580-A1 | Immunotherapy | Pending | 01-Jul-2020 | ||
| EP-4175649-A1 | Immunotherapy | Pending | 01-Jul-2020 | ||
| JP-2026146116-A | Immunotherapy | Pending | 01-Jul-2020 | ||
| US-20230310608-A1 | Immunotherapy | Pending | 01-Jul-2020 | A61K39/00119 |
Neogap Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neogap Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Swedish-American Chamber of Commerce - New York | Accelerator/Incubator | |||
| Northislet | Growth/Expansion | Minority | ||
| Phase2Phase Biopharma | Venture Capital | Minority | ||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| 3T Invest | Venture Capital | Minority |
Neogap Investments & Acquisitions (2)
Neogap’s most recent deal was a Secondary Transaction - Private with TCER Oncology. The deal was made on 21-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TCER Oncology | 21-Jun-2023 | Secondary Transaction - Private | Drug Discovery | ||
| TCER Oncology | Merger/Acquisition | Drug Discovery |
Neogap FAQs
-
When was Neogap founded?
Neogap was founded in 2016.
-
Where is Neogap headquartered?
Neogap is headquartered in Solna, Sweden.
-
What is the size of Neogap?
Neogap has 25 total employees.
-
What industry is Neogap in?
Neogap’s primary industry is Drug Discovery.
-
Is Neogap a private or public company?
Neogap is a Private company.
-
What is Neogap’s current revenue?
The current revenue for Neogap is .
-
How much funding has Neogap raised over time?
Neogap has raised $20.9M.
-
Who are Neogap’s investors?
Swedish-American Chamber of Commerce - New York, Northislet, Phase2Phase Biopharma, European Innovation Council, and 3T Invest are 5 of 8 investors who have invested in Neogap.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
